中国成人2型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识

被引:91
作者
中华医学会糖尿病学分会
中华医学会内分泌学分会
机构
[1] 中华医学会糖尿病学分会
[2] 中华医学会内分泌学分会
基金
国家重点研发计划;
关键词
糖尿病, 2型; 糖化血红蛋白; 动脉粥样硬化性心血管疾病; 心力衰竭; 慢性肾脏疾病;
D O I
暂无
中图分类号
R587.1 [糖尿病];
学科分类号
100201 [内科学];
摘要
糖化血红蛋白(HbA1c)控制目标应遵循患者为中心的个体化原则, 即根据患者的年龄、病程、健康状况、药物不良反应风险等因素实施分层管理。本共识建议一般成人2型糖尿病(T2DM)患者的HbA1c控制目标为<7.0%, 并对其他情况下的HbA1c目标值作出推荐。此外, 本共识建议将二甲双胍作为T2DM患者单药治疗的首选, α-糖苷酶抑制剂(AGI)或胰岛素促泌剂作为单药治疗的备选。进行联合治疗时, 建议根据患者是否合并动脉粥样硬化性心血管疾病(ASCVD)、心力衰竭(HF)或慢性肾脏疾病(CKD)进行分层。如患者合并ASCVD, 建议在具备条件的情况下联合有心血管获益证据的胰高糖素样肽-1受体激动剂(GLP-1RA)或钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)。如患者合并CKD, 建议联合用药时在条件允许的情况下首选有肾脏获益证据的SGLT2i, 在患者不能使用SGLT2i时可选择有肾脏获益证据的GLP-1RA。如患者合并HF, 建议在条件允许时选择SGLT2i。如患者不合并ASCVD、HF或CKD, 可根据基线HbA1c水平、低血糖风险、体重、经济状况、药物可及性等因素选择联合的药物。
引用
收藏
相关论文
共 43 条
[1]
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J].
McMurray, J. J. V. ;
Solomon, S. D. ;
Inzucchi, S. E. ;
Kober, L. ;
Kosiborod, M. N. ;
Martinez, F. A. ;
Ponikowski, P. ;
Sabatine, M. S. ;
Anand, I. S. ;
Belohlavek, J. ;
Bohm, M. ;
Chiang, C. -E. ;
Chopra, V. K. ;
de Boer, R. A. ;
Desai, A. S. ;
Diez, M. ;
Drozdz, J. ;
Dukat, A. ;
Ge, J. ;
Howlett, J. G. ;
Katova, T. ;
Kitakaze, M. ;
Ljungman, C. E. A. ;
Merkely, B. ;
Nicolau, J. C. ;
O'Meara, E. ;
Petrie, M. C. ;
Vinh, P. N. ;
Schou, M. ;
Tereshchenko, S. ;
Verma, S. ;
Held, C. ;
DeMets, D. L. ;
Docherty, K. F. ;
Jhund, P. S. ;
Bengtsson, O. ;
Sjostrand, M. ;
Langkilde, A. -M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :1995-2008
[2]
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial [J].
Rosenstock, Julio ;
Kahn, Steven E. ;
Johansen, Odd Erik ;
Zinman, Bernard ;
Espeland, Mark A. ;
Woerle, Hans J. ;
Pfarr, Egon ;
Keller, Annett ;
Mattheus, Michaela ;
Baanstra, David ;
Meinicke, Thomas ;
George, Jyothis T. ;
von Eynatten, Maximilian ;
McGuire, Darren K. ;
Marx, Nikolaus .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12) :1155-1166
[3]
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [J].
Perkovic, V. ;
Jardine, M. J. ;
Neal, B. ;
Bompoint, S. ;
Heerspink, H. J. L. ;
Charytan, D. M. ;
Edwards, R. ;
Agarwal, R. ;
Bakris, G. ;
Bull, S. ;
Cannon, C. P. ;
Capuano, G. ;
Chu, P. -L. ;
De Zeeuw, D. ;
Greene, T. ;
Levin, A. ;
Pollock, C. ;
Wheeler, D. C. ;
Yavin, Y. ;
Zhang, H. ;
Zinman, B. ;
Meininger, G. ;
Brenner, B. M. ;
Mahaffey, K. W. ;
McGuire, Darren K. ;
Holman, Rury ;
Home, Philip ;
Scharfstein, Dan ;
Parfrey, Patrick ;
Shahinfar, Shahnaz ;
August, Phyllis ;
Chang, Tara ;
Sinha, Arjun D. ;
Januzzi, James ;
Kolansky, Daniel ;
Amerena, John ;
Hillis, Graham ;
Gorelick, Philip ;
Kissela, Brett ;
Kasner, Scott ;
Lindley, Richard ;
Fulcher, Greg ;
Ounadjela, Souhila ;
Hufert, Karina ;
von Ingersleben, Gabriele ;
Gaglia, Jason ;
Harris, Ronald ;
Hudson, Margo ;
Turchin, Alexander ;
Cheifetz, Adam .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) :2295-2306
[4]
Intensive Glucose Control in Patients with Type 2 Diabetes-15-Year Follow-up [J].
Reaven, Peter D. ;
Emanuele, Nicholas V. ;
Wiitala, Wyndy L. ;
Bahn, Gideon D. ;
Reda, Domenic J. ;
McCarren, Madeline ;
Duckworth, William C. ;
Hayward, Rodney A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) :2215-2224
[5]
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline..[J].LeRoith Derek;Biessels Geert Jan;Braithwaite Susan S;Casanueva Felipe F;Draznin Boris;Halter Jeffrey B;Hirsch Irl B;McDonnell Marie E;Molitch Mark E;Murad M Hassan;Sinclair Alan J.The Journal of clinical endocrinology and metabolism.2019, 5
[6]
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2019 EXECUTIVE SUMMARY [J].
Garber, Alan J. ;
Abrahamson, Martin J. ;
Barzilay, Joshua L. ;
Blonde, Lawrence ;
Bloomgarden, Zachary T. ;
Bush, Michael A. ;
Dagogo-Jack, Samuel ;
DeFronzo, Ralph A. ;
Einhorn, Daniel ;
Fonseca, Vivian A. ;
Garber, Jeffrey R. ;
Garvey, W. Timothy ;
Grunberger, George ;
Handelsman, Yehuda ;
Hirsch, Irl B. ;
Jellinger, Paul S. ;
McGill, Janet B. ;
Mechanick, Jeffrey L. ;
Rosenblit, Paul D. ;
Umpierrez, Guillermo E. .
ENDOCRINE PRACTICE, 2019, 25 (01) :69-100
[7]
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes [J].
Wiviott, S. D. ;
Raz, I. ;
Bonaca, M. P. ;
Mosenzon, O. ;
Kato, E. T. ;
Cahn, A. ;
Silverman, M. G. ;
Zelniker, T. A. ;
Kuder, J. F. ;
Murphy, S. A. ;
Bhatt, D. L. ;
Leiter, L. A. ;
McGuire, D. K. ;
Wilding, J. P. H. ;
Ruff, C. T. ;
Gause-Nilsson, I. A. M. ;
Fredriksson, M. ;
Johansson, P. A. ;
Langkilde, A-M. ;
Sabatine, M. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04) :347-357
[8]
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].
Zelniker, Thomas A. ;
Wiviott, Stephen D. ;
Raz, Itamar ;
Im, Kyungah ;
Goodrich, Erica L. ;
Bonaca, Marc P. ;
Mosenzon, Ofri ;
Kato, Eri T. ;
Cahn, Avivit ;
Furtado, Remo H. M. ;
Bhatt, Deepak L. ;
Leiter, Lawrence A. ;
McGuire, Darren K. ;
Wilding, John P. H. ;
Sabatine, Marc S. .
LANCET, 2019, 393 (10166) :31-39
[9]
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J].
Davies, Melanie J. ;
D'Alessio, David A. ;
Fradkin, Judith ;
Kernan, Walter N. ;
Mathieu, Chantal ;
Mingrone, Geltrude ;
Rossing, Peter ;
Tsapas, Apostolos ;
Wexler, Deborah J. ;
Buse, John B. .
DIABETES CARE, 2018, 41 (12) :2669-2701
[10]
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial [J].
Muskiet, Marcel H. A. ;
Tonneijck, Lennart ;
Huang, Yao ;
Liu, Minzhi ;
Saremi, Aramesh ;
Heerspink, Hiddoj L. ;
van Raalte, Daniel H. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (11) :859-869